Key Takeaways DexCom delivered double-digit Q3 growth and raised full-year guidance on strong CGM demand.Expanded U.S. and international reimbursement is fueling broader CGM adoption and patient starts.New software, G7, One , and Stelo launches are boosting engagement and supporting long-term growth.DexCom, Inc. (DXCM) is well-poised for growth in the coming quarters, backed by a huge potential in the CGM market. A strong third-quarter 2025 performance and a series of favorable coverage decisions are expect ...